. The definitive diagnosis is histological but S-AFP determination is used in making a presumptive diagnosis. Although patients with hepa-
in the diagnosis ofhepatoma must be made. We took data on the sensitivity and specificity of different diagnostic S-AFP concentrations from the literature and evaluated them statistically and by Bayesian analysis. In our patients (hepatoma prevalence 0 028) a sensitive diagnostic concentration (30-50 ng/ml) will misdiagnose hepatoma so often that a positive test will indicate hepatoma in only 10% of cases. A positive test at a specific diagnostic concentration (500 ng/ml) indicates hepatoma in 100% of cases and is preferable in terms of cost benefit. Although the lower concentration will diagnose a larger proportion of patients with hepatoma (740% compared with 59 %) the 'costs' of excluding false positives are considerable (A$2545 per extra case with 2-5 % of patients suffering significant morbidity). In western societies, where the prevalence of hepatoma is low, a higher, less sensitive but more specific diagnostic S-AFP concentration is appropriate.
Methodological advances have enabled accurate and reproducible measurements to be made of minute amounts of substances in biological fluids. Unfortunately there is usually an overlap between the diseased and the non-diseased population tested and as an investigation becomes more sensitive' it becomes less specific.2 The use of serum alphal-fetoprotein (S-AFP) determination in the diagnosis of primary hepatocellular carcinoma (hepatoma) illustrates that the choice between sensitivity and specificity can be a calculated one.
Hepatoma often presents a diagnostic problem since its clinical manifestations are protean and it is usually associated with long-standing cirrhosis (Ihde et al., 1974) . The definitive diagnosis is histological but S-AFP determination is used in making a presumptive diagnosis. Although patients with hepa-2A specific test is one which correctly identifies nondiseased patients. It is negative in non-diseased patients and has a low false positive ratio (Galen and Gambino, 1976 (Ruoslahti and Seppala, 1972a; Purves and Purves, 1972; Chayvialle and Ganguli, 1973) . There is obviously an optimal diagnostic concentration which will identify most hepatoma patients and not misdiagnose too many non-hepatoma patients, but it has not been defined (Kew, 1974) . This uncertainty can be partly resolved by statistical analyses. By plotting the true positive (TP) ratio' against the false positive (FP) ratio2 a curve called the 'receiver operating-characteristic' (ROC) can be constructed (McNeil et al., 1975) (Fig. 1) . The curve joins (0,0) the most specific position (where no diseased but all normal patients are correctly diagnosed) to (1,1) the most sensitive position (where all diseased but no normal patients are correctly diagnosed). The optimal operating position lies somewhere between these two points and occurs where the slope of the ROC curve equals (Swets et al., 1964) two. S-AFP was measured by an immunodiffusion technique (limit of detection 500 ng/ml) (Kohn, lifferent diagnostic serum AFF 1970) with 10 positive (range 500-70 000 ng/ml) and refer to references from which seven negative results (TP ratio = 0-59). There were Table 1 ).
no false positive results in 581 other patients, most of whom had been diagnosed as having cirrhosis. Table 1 Zawadski and Kraj (1974) and dangerous to the normal patient a specific test is appropriate and one uses a position to the left where the slope is high. The ROC curve can also be used to determine the additional information gained by performing the test (Metz et al., 1973 points where the additional information gained by the test was maximal (the Imax points) for these three hepatoma prevalences (Fig. 2) .1 COSTING The optimal operating position determined by the cost benefit analysis using the ROC curve takes the 'costs' of false positive and negative results into account. Alternatively, two diagnostic S-AFP concentrations may be compared by determining how much it 'costs' to diagnose an extra case by the more sensitive investigative strategy.
For simplicity, only two diagnostic S-AFP concentrations were considered: this study's less sensitive, more specific concentration A and a more sensitive, less specific concentration B determined by radioimmunoassay with characteristics determined from the ROC curve (50-100 ng/ml; TP ratio = 0 93, FP ratio = 0 20), (Ruoslahti and Seppala, 1972b; Chayvialle et al., 1974) .
We assumed that if the patient's S-AFP concentration was greater than A in the appropriate clinical "We would be pleased to supply interested readers with tables showing the source of data used in constructing the ROC curve, the details of the costing structure used, and the co-ordinates of the Imax points and optimal operating positions.
setting the diagnosis would be considered established and no further investigations would be performed. If the patient's S-AFP concentration was less than A but greater than B a liver scan would be performed. If this were positive a scan-guided percutaneous liver biopsy would be performed to establish the diagnosis. If the patient's S-AFP concentration was less than B hepatoma would be considered to be excluded. Table  2 gives the data concerning the investigations which were used in the calculation of costs for the two diagnostic S-AFP concentrations: the TP and FP ratios, morbidity, and mortality were taken from the literature (Ludbrook et al., 1972; Conn, 1972; Zamcheck and Klausenstock, 1953; Terry, 1952) and the costs quoted are local ones.
By Bayesian analysis The probability of hepatoma in a patient whose S-AFP concentration was positive or negative at concentration A or concentration B was calculated by Bayesian analysis using the TP and FP ratios and three prevalences quoted above.
Results Fig. 2 shows that the Imax points and the positions of the optimal diagnostic S-AFP concentrations for the three prevalences are closer to the position of A than to the position of B. The superiority of the less sensitive diagnostic S-AFP concentration is most marked at a low prevalence hepatoma. Table 3 shows the yield and cost per hepatoma diagnosed by using the less sensitive diagnostic concentration (A) or the more sensitive diagnostic concentration (B) followed by confirmatory investigations. The marginal cost of the more sensitive investigative procedure (the cost of diagnosing each case not diagnosed by using diagnostic concentration A alone) is large ($A2545 for the hepatoma prevalence of this series) and there is significant morbidity. tConn (1972) . $Cost of liver biopsy includes local fees for a 24-hour hospital stay, the biopsy procedure, clotting studies, and blood grouping and matching. §Mortality 0-17% (Zamcheck and Klausenstock, 1953) . Morbidity 0-325% (Terry, 1952) . tMorbidity is the number of patients suffering investigative ill effects per 100 extra cases diagnosed by using diagnostic concentration B and confirmatory investigations but missed by using diagnostic concentration A alone. Table 4 shows that if the S-AFP concentration is A for the hepatoma prevalence of this series (01028) hepatoma will be present in 100% of cases, whereas if it is B hepatoma will be present in only 12% of cases.
Discussion
Hepatoma is uncommon in western societies and may by suspected in any patient with deteriorating cirrhosis. If S-AFP is measured to diagnose hepatoma our analyses show that the routine use of a more specific, less sensitive diagnostic S-AFP concentration is appropriate. We do not have enough data on the use of S-AFP measurement for diagnosing hepatoma in other groups of patients. A therapeutic enthusiast might think that measurement of S-AFP concentrations might be useful in detecting hepatoma in patients at risk when the disease is preclinical and treatment might be more effective. Given the likely hepatoma prevalence and TP and FP ratios, however, such screening would mean a large number of patients undergoing further investigations for a small yield. The results of our analyses in cirrhotic patients are affected by the probability of hepatoma before measurement of S-AFP. Although the usual hepatoma probability in tested patients is low (< 0103) there are occasional patients in whom the clinician strongly suspects a hepatoma and the probability may be higher (for example, 0 05-0-5). Theoretically there is an optimal operating position on the ROC curve of a test (S-AFP determination) for a particular prevalence of disease (hepatoma) and that point could be used in diagnosis. An approach to the ideal is possible if an ROC curve is constructed and if the disease probability in the individual patient is estimated by a scoring system of clinical and other features. An operating position (diagnostic S-AFP concentration) can be selected to maximise information or minimise costs. The laboratory can then report the optimal diagnostic serum concentration with the quantitative result or state that the result was positive ornegativeat this concentration. Alternatively the probability of a particular test result (S-AFP concentration) indicating disease (hepatoma) in an individual patient can be calculated and reported with the result. This is easily done by using the ROC curve to determine the FP and TP ratios associated with the patient's result, the clinician's estimate of the patient's disease probability, and Bayes's formula. The appropriate operating position on the ROC curve and the disease probability are easily calculated by a computer and would aid in interpreting the test result.
We used statistical methods to develop a rational approach to the use of a test (AFP determination) in the diagnosis of a disease (hepatoma). Although some details are peculiar to the locality the methods are generally applicable. For hepatoma, whatever the method of measuring S-AFP, a less sensitive, more specific diagnostic concentration (500 ng/ml) should be used for the usual western population and a more sensitive, less specific diagnostic concentration (50-100 ng/ml) should be used only for special patient populations with a high prevalence of hepatoma. 
